Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.

The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome. The initial maintenance dose was determined by acid inhibition studies. In all patients lansoprazole controlled gastric acid hypersecretion and peptic symptoms in both the short and long term. Patients were treated for a mean of 31 months (range 1-43 months) with all but 4 patients followed for > 18 months. The mean initial dose was 60 mg/day, with 2 patients requiring a twice daily dose and the others a single daily dose. During long-term treatment 6 patients required an increased dosage, 5 within the first year. Long-term maintenance doses were reduced in 5 of the 6 patients in whom this was attempted. No changes in serum gastrin concentration, haematological parameters, liver function studies or other biochemical parameters occurred due to lansoprazole. No patient developed a gastric carcinoid tumour while being treated with lansoprazole. These results demonstrate that long-term treatment with lansoprazole is both safe and effective in patients with Zollinger-Ellison syndrome, and suggest that this drug will be useful in such patients. Furthermore, maintenance doses of lansoprazole, determined by the currently recommended method of acute acid titration studies in patients with Zollinger-Ellison syndrome, are too high.
AuthorsR T Jensen, D C Metz, P D Koviack, K M Feigenbaum
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 7 Suppl 1 Pg. 41-50, discussion 61-6 ( 1993) ISSN: 0269-2813 [Print] ENGLAND
PMID8490079 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Gastrins
  • Lansoprazole
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Omeprazole
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Alanine Transaminase (metabolism)
  • Anti-Ulcer Agents (adverse effects, therapeutic use)
  • Aspartate Aminotransferases (metabolism)
  • Drug Administration Schedule
  • Fasting (blood)
  • Female
  • Follow-Up Studies
  • Gastrins (blood)
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole (adverse effects, analogs & derivatives, therapeutic use)
  • Prospective Studies
  • Zollinger-Ellison Syndrome (blood, drug therapy, enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: